60,363 Shares in Q32 Bio Inc. $QTTB Bought by Carlyle Group Inc.

Carlyle Group Inc. purchased a new stake in shares of Q32 Bio Inc. (NASDAQ:QTTB) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 60,363 shares of the company’s stock, valued at approximately $769,000. Q32 Bio accounts for approximately 0.0% of Carlyle Group Inc.’s portfolio, making the stock its 13th largest holding. Carlyle Group Inc. owned approximately 0.36% of Q32 Bio as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Marshall Wace LLP acquired a new position in shares of Q32 Bio during the 2nd quarter worth about $25,000. Acadian Asset Management LLC bought a new stake in Q32 Bio during the 1st quarter valued at approximately $50,000. Two Sigma Investments LP acquired a new stake in Q32 Bio in the 3rd quarter valued at approximately $62,000. ADAR1 Capital Management LLC acquired a new stake in Q32 Bio in the 4th quarter valued at approximately $66,000. Finally, AQR Capital Management LLC bought a new position in Q32 Bio in the 1st quarter worth approximately $68,000. 31.32% of the stock is owned by institutional investors and hedge funds.

Q32 Bio Stock Up 5.3%

Q32 Bio stock opened at $15.95 on Tuesday. The business has a 50 day moving average price of $14.29 and a two-hundred day moving average price of $9.00. The stock has a market cap of $474.83 million, a price-to-earnings ratio of 5.32 and a beta of 0.23. Q32 Bio Inc. has a 12 month low of $1.62 and a 12 month high of $23.57.

Q32 Bio (NASDAQ:QTTB) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.02. On average, analysts expect that Q32 Bio Inc. will post -1.53 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Diyong Xu bought 1,875,000 shares of Q32 Bio stock in a transaction that occurred on Thursday, May 28th. The stock was purchased at an average cost of $8.00 per share, with a total value of $15,000,000.00. Following the completion of the transaction, the director directly owned 3,502,987 shares in the company, valued at $28,023,896. This trade represents a 115.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Orbimed Advisors Llc purchased 1,875,000 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were acquired at an average price of $8.00 per share, for a total transaction of $15,000,000.00. Following the purchase, the director directly owned 3,502,987 shares of the company’s stock, valued at approximately $28,023,896. This represents a 115.17% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 34.46% of the company’s stock.

Analyst Upgrades and Downgrades

QTTB has been the subject of a number of research analyst reports. Oppenheimer upped their price target on Q32 Bio from $20.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. HC Wainwright raised their price objective on shares of Q32 Bio from $13.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Cantor Fitzgerald began coverage on shares of Q32 Bio in a research report on Monday, May 18th. They set an “overweight” rating on the stock. Mizuho started coverage on shares of Q32 Bio in a research note on Friday, May 22nd. They set an “outperform” rating and a $14.00 target price for the company. Finally, Zacks Research downgraded shares of Q32 Bio from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.00.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.